Genflow Biosciences PLC (LSE:GENF) said it is confident about its future following three recent strategic collaborations in longevity research allied to a strong cash position.
In March, Genflow commenced a scientific research collaboration with the University of Rochester's Aging Research Center (RoAR), one of the world's pre-eminent age research facilities.
Data obtained from the collaboration will support the pre-clinical trials Genflow is undertaking and will expedite its development of gene therapies.
In May, the company entered into a collaborative research agreement with Organips, a France-based biotechnology company, while in June it partnered with Magnitude Biosciences, a UK-based, specialist biotechnology research organisation that supports drug discovery and product development.
Working with Magnitude will significantly expedite Genflow's future therapeutic developments, the company said.
Cash and equivalents at the end of the half year to June 2022, meanwhile, were £2.95mln following a standard market listing in January that raised £3.5mln.
Losses in the period were £773,000 (£374,000).